Nashville, Tennessee-based CopilotIQ and Boston, Massachusetts-based Biofourmis have announced a strategic merger between the two companies.
Biofourmis is a global technology-enabled care delivery company, delivering in-home care solutions serving enterprise healthcare customers. Driven by data and FDA-cleared algorithms, the Biofourmis platform delivers interventions personalized to the individual and their disease. It’s configurable and scaleable, to adapt to the needs of organizations and patient populations. Biofourmis has received funding from both General Atlantic and Openspace Ventures.
CopilotIQ, which launched in 2021, offers at-home remote health monitoring for older patients. The company’s platform combines continuous biomarker data, behavioral analytics and U.S.-licensed nursing visits to better manage chronic conditions, with a particular focus on hypertension and diabetes. CopilotIQ has raised $30 million in seed and series A funding rounds, both led by Bessemer Venture Partners.
The combined company creates the first AI-driven platform that delivers in-home care across the full spectrum from pre-surgical optimization to acute, post-acute, and chronic care. Leading investors from both businesses, including General Atlantic, Openspace Ventures and Bessemer Venture Partners, are investing in the combined business. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the 206th eHealth transaction of 2024, and the 20th in the remote patient monitoring specialty. There were 22 RPM deals announced during 2023, and 16 announced during 2022.
